Zafgen, Inc.
| Company Name | Zafgen, Inc. |
| Stock Symbol | ZFGN |
| Class Period | June 19, 2014 to October 16, 2015 |
| Lead Plaintiff Motion Deadline | December 21, 2015 |
The Firm is investigating potential claims on behalf of investors of Zafgen, Inc. investors ("Zafgen" or the "Company") (Nasdaq: ZFGN) concerning the Company’s and its officers’ possible violations of federal securities laws.
On October 16, 2015, Zafgen disclosed that it received verbal notice from the U.S. Food and Drug Administration that the clinical trials involving beloranib, a drug designed to reduce hunger while stimulating the use of stored fat as an energy source, have been placed on partial hold following the death of a patient enrolled in a beloranib trial. Additionally, news reports allege that the company disclosed that six patients in previous and current trials reported thrombotic adverse events, including blood clots in the legs, and more seriously, in the lungs, and that all six patients were treated with beloranib.
On this news, the Company’s stock price fell as much as $8.50, or 40%, during intra-day trading on October 16, 2015.
If you purchased Zafgen securities and have suffered a loss on your investment, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224 or by e-mail to shareholders@glancylaw.com.
Submit Your Information
If you suffered a loss on your Zafgen, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.